Last update 01 Nov 2024
Dignity Sciences Ltd.

Dignity Sciences Ltd.

Private Company|
2010|
Ireland
|
10-50
|
www.dsbiopharma.com

Overview

Tags

Neoplasms
Congenital Disorders
Immune System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
D5D(fatty acid desaturase 1)2

Related

9
Drugs associated with Dignity Sciences Ltd.
Mometasone Furoate
Target
GR
Mechanism
GR agonists
Active Org.
Shanghai Lianbio Development Co., Ltd.Shanghai Lianbio Development Co., Ltd. [+9]
Originator Org.
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Active Indication
Chronic rhinosinusitis with nasal polyps [+14]
Inactive Indication
Acute sinusitis [+17]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date30 Apr 1987
Hydrocortisone Butyrate
Target
GR
Mechanism
GR agonists
Active Org.
Bausch Health Americas, Inc. [+3]
Originator Org.
Astellas Pharma Europe BV
Active Indication
Dermatitis, Atopic [+2]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date31 Mar 1982
Daleuton
Target
D5D
Mechanism
D5D inhibitors
Active Org.
Dignity Sciences Ltd.Dignity Sciences Ltd.
Originator Org.
Dignity Sciences Ltd.Dignity Sciences Ltd.
Active Indication
Dermatitis, Atopic [+2]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
13
Clinical Trials associated with Dignity Sciences Ltd.
NCT03817190 / TerminatedPhase 2
A Randomised, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
EUCTR2017-004098-15-EE / Not yet recruitingPhase 2
A Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Assessthe Efficacy and Safety of Orally Administered DS107 in a once daily doseof 2g in Haemodialysis Patients with Moderate to Severe Uremic Pruritus
NCT02864498 / CompletedPhase 2
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
100 Clinical Results associated with Dignity Sciences Ltd.
Login to view more data
0 Patents (Medical) associated with Dignity Sciences Ltd.
Login to view more data
100 Deals associated with Dignity Sciences Ltd.
Login to view more data
100 Translational Medicine associated with Dignity Sciences Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
Phase 3 Clinical
Other
7
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Daleuton
 ( D5D )		Dermatitis, Atopic
More
Phase 3
DS-112
 ( D5D )		Solid tumor
More
Preclinical
DS-111
Rare Diseases
More
Discontinued
DS-108
Skin Diseases
More
Discontinued
Diroleuton
 ( IL-10 )		Dermatitis, Atopic
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free